Biochemical prenatal tests and uterine artery Doppler examination in prediction of PIH and IUGR in the third trimester of pregnancy;Biochemiczne testy prenatalne i badanie dopplerowskie tetnic macicznych w predykcji PIH i IUGR w III trymestrze ciaży

Ginekologia Polska

Volumn 81, Issue 5, 2010, Pages 352-357

  Katarzyna, Słowakiewicz ^a   Małgorzata, Perenc ^a   Piotr, Sieroszewski ^a  

^a Klinika Medycyny P odu i Ginekologii   (Poland)

Author keywords

Doppler ultrasonography; Fetal growth retardation; Pregnancy induced hypertention; Prenatal diagnosis

Indexed keywords

EID: 77954546205     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Breborowicz G.H. Ciaża wysokiego ryzyka. Wyd. II roz. Poznań: Ośrodek Wydawnictw Naukowych. 2006.
2. Granger J, Alexander B, Bennett W, [et al.]. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens. 2001, 14, 178S-185S.
3. Wegrzyn P, Fiegler P, Kamiński K. Etiologia wewnatrzmacicznego opóźnionego wzrastania płodu. Cześć I. Czynniki zwiazane z zaburzeniami jednostki płodowo-łożyskowej. Cześć IICzynniki pochodzenia matczynego. Ginekol Pol. 2004; 75, 303-316.
4. Antsaklis A, Papantoniou N, Mesogitis S, [et al.]. Pregnant women of 35 years of age or more: maternal serum markers or amniocentesis? J Obstet Gyneacol. 1999, 19, 253-256.
5. Dugoff L, Hobbins J, Malone F, [et al.]. First trimester maternal serum PAPP- a and free β subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population based study (The Faster Trial). Am J Obstet Gynecol. 2004, 191, 1446-1451.
6. Smith G, Shah J, Crossley J, [et al.]. Pregnancy associated plasma protein A and alphafetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol. 2006, 107, 161-166.
7. Burton B. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol. 1988, 72, 709-713.
8. Sorensten T, Williams M, Zingheim R, [et al.]. Elevated second trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol. 1993, 169, 834-838.
9. Williams M, Hickok D, Zingheim R, [et al.]. Elevated maternal serum - fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. Am J Obstet Gynecol. 1992, 167, 1032-1037.
10. Yaron Y, Cherry M, Kramer R, [et al.]. Second trimester maternal serum marker screening: maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999, 181, 968-974.
11. Palacio M, Jauniaux E. Kingdom J, [et al.]. Perinatal outcome in pregnancies with a positive serum screening for Down's Syndrome due to elevated levels of free βhuman chorionic gonadotropin. Ultrasound Obstet Gynecol. 1999, 13, 58-62.
12. Mires G, Williams F, Leslie J, [et al.]. Assessment of uterine arterial notching as a screening test for adverse pregnancy outcome. Am J Obstet Gynecol. 1998, 179, 1317-1323.
13. Mires G, Christie A, Leslie J, [et al.]. Are "notched" uterine arterial waveforms of prognostic value for hypertensive and growth disorders of pregnancy? Fetal Diagn Ther. 1995, 10, 111-118.
14. Sieroszewski P, Guzowski G, Sosnowski D, [i wsp.]. Badanie Doplerowskie tetnic macicznych w diagnostyce ciaż wysokiego ryzyka położniczego (powikłanych nadciśnieniem i/lub hipotrofia płodu). Ginekol Pol. 2005, 76, 342-347.
15. Sieroszewski P, Guzowski G. Wartość prognostyczna badania Dopplerowskiego tetnic macicznych w 20-24 tygodniu ciaży dla wystapienia nadciśnienia indukowanego ciaża I hipotrofii płodu. Ginekol Pol. 2005, 76, 348-357.
16. Sieroszewski P, Suzin J, Karowicz-Bilińska A. Ultrasonograficzna ocean leczenia hipotrofii płodu przy użyciu donora NO (L-arginina). Ginekol Pol. 2004, 75, 913-918.
17. Leitich H, Egarter C, Husslein P, [et al.]. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. Br J Obstet Gynaecol. 1997, 104, 450-459.
18. Coomarasamy A, Honest H, Papaioannou S, [et al.]. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003, 101, 1319-1332.
19. Tanaka M, Natori M, Kohno H, [et al.]. Fetal growth in patients with elevated maternal serum hCG levels. Obstet Gynecol. 1993, 81, 341-343.
20. Muller F, Savey L, Le Fiblec B, [et al.]. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. Am J Obstet Gynecol. 1996, 175, 37-40.
21. Vaillant P, David E, Constant I, [et al.]. Validity in nulliparas of increased beta-human chorionic gonadotrophin at mid-term for predicting pregnancy-induced hypertension complicated with proteinuria and intrauterine growth retardation. Nephron. 1996, 72, 557-563.
22. Ashour A, Lieberman E, Haug L, [et al.]. The value of elevated second-trimester beta-human chorionic gonadotropin in predicting development of preeclampsia. Am J Obstet Gynecol. 1997, 176, 438-442.
23. Gonen R, Perez R, David M, [et al.]. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol. 1992, 80, 83-86.
24. Jones C, Fox H. An ultrastructural and ultrahistochemical study of the human placenta in maternal pre-eclampsia. Placenta. 1980, 1, 61-76.
25. Cnossen J, Morris R, ter Riet G, [et al.]. Use of uterine artery Doppler ultrasonography to predict preeclampsia and intrauterine growth restriction: a systematic review and bivariable metaanalysis. CMAJ. 2008, 178, 701-711.
26. Coleman M, McCowan L, North R. Mid-trimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high-risk women. Ultrasound Obstet Gynecol. 2000, 15, 7-12.
27. Ohkuchi A, Minakami H, Sato I, [et al.]. Predicting the risk of pre-eclampsia and a small-forgestational-age infant by quantitative assessment of the diastolic notch in uterine artery flow velocity waveforms in unselected women. Ultrasound Obstet Gynecol. 2000, 16, 171-178.